NEW YORK, Oct. 26 (GenomeWeb News) - Thermo Electron and Massachusetts General Hospital have opened the doors to a new facility designed to develop mass-spectrometry-based technologies for protein biomarker discovery, the company said today.
The 3,000-square-foot space, called the Biomarker Research Initiatives in MassSpectrometryCenter, or BRIMS, is based in Cambridge, Mass.. It was slated to open in the beginning of next year, according to ProteoMonitor, a GenomeWeb News publication that reported on the center on Oct. 15.
Mass General brings to the table basic research aimed at identifying biomarkers for cardiovascular disease. Thermo Electron will assign a team for research into mass spectrometry, protein techniques, and informatics.
Leo Bonilla, the head of the new center, said the facility will house Thermo-made hybrid LTQ-FT, LTQ-FT, LTQ, and triple quadrupole mass spectrometers; freezers; speed vacs; and a sizable IT infrastructure put together by IBM Life Sciences, according to ProteoMonitor. Click here to read the full article.
"It will be nice to have one place where you can actually do all the steps of the experiment," Bonilla told the newsletter. "Right now we collect at [Massachusetts GeneralHospital], then we fractionate some of the samples at Bill Hancock's lab at Northeastern [University], and we also do a lot of the affinity capturing of glycoproteins in his lab. With this new center, the samples will go directly from the freezers at MGH to our freezers in the center."
It was unclear how much Thermo would spend on equipping the new center and leasing the portion of the Cambridgebuilding to be used for the center.
In collaboration with MGH and other Bostonresearch institutions, including Harvard medical school, Brigham and Women's Hospital and Children's Hospital, Thermo began working on the discovery of biomarkers for cardiovascular disease in 2001. The idea for the center grew out of the cardiovascular research and company initiatives to fund areas of strategic growth.